{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"12","value":"11"}]}],"title":"Neutrophil Engraftment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"20","value":"15"}]}],"title":"Platelet Engraftment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Engraftment is assessed as:\n\n* Neutrophil engraftment is \\> 0.5 x 10⁹/L after cytopenia\n* Platelet engraftment is \\> 20 x 10⁹/L after cytopenia","dispersionType":"Full Range","groups":[{"description":"Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.","id":"OG000","title":"Autologous-Allogeneic Hematopoietic Stem Cell Transplant"}],"paramType":"MEDIAN","populationDescription":"Includes all study participants","reportingStatus":"POSTED","timeFrame":"1 month","title":"Median Time to Engraftment After Auto-PBSC Transplant","type":"SECONDARY","unitOfMeasure":"Days"}